Decentralized Procedure, DCP, MAA Submissions, CMS, RMS, MAH
Freyr support pharma manufacturers in MAA submission for generic medical product submissions through Decentralized Procedure (DCP) to all selected EU member states (RMS & CMS) as per the regional Health Authorities (HAs)
If a market authorization applicant is not granted authorization by any of the European Union (EU) member states, and is aiming for procuring authorization in multiple selected EU member states, then they can approach the Health Authority (HA) through Decentralized Procedure (DCP).
The applicant can request any one of the EU member states to act as reference member state (RMS) and submit the market authorization application (MAA) to all selected EU member states (RMS and concerned member states [CMS]). The review cycle for the approval of MAA would be about 210 days, including a 30-day national phase to translate the product information in regional language.
If a market authorization applicant is not granted authorization by any of the European Union (EU) member states, and is aiming for procuring authorization in multiple selected EU member states, then they can approach the Health Authority (HA) through Decentralized Procedure (DCP).
The applicant can request any one of the EU member states to act as reference member state (RMS) and submit the market authorization application (MAA) to all selected EU member states (RMS and concerned member states [CMS]). The review cycle for the approval of MAA would be about 210 days, including a 30-day national phase to translate the product information in regional language.
Comments
Post a Comment